CLINICAL_TRIALS
trial_result
· 2008-02-13
Clinical Trial Update: Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases [Phase 1]
Summary
A Phase 1 multiple-dose study of MPC-6827 in subjects with refractory brain metastases has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Myrexis Inc. | Conditions: Brain Neoplasms | Phase 1 | Status: COMPLETED